HR 2883 · 117th Congress · Health

Stop Stalling Access to Affordable Medications

Introduced 2021-04-28· Sponsored by Rep. Jeffries, Hakeem S. [D-NY-8]· House

Bill Progress

Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 31 - 9.(2021-09-29)

Plain Language Summary

[AI summary unavailable — showing source text] Stop Stalling Access to Affordable Medications This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.…

Summarized by Claude AI · Non-partisan · For informational purposes only

CBO Cost Estimate

Congressional Budget Office

Estimated Budgetary Effects of H.R. 2883, the Stop Stalling Access to Affordable Medications Act

Jul 22, 2022

As ordered reported by the House Committee on the Judiciary on September 29, 2021

Full CBO report ↗

Official non-partisan budget analysis by the Congressional Budget Office

Cosponsors (8)

5 Democrats3 Republicans